OI . | Drug . | Patients . | |||||
---|---|---|---|---|---|---|---|
PCP | ST | PM | |||||
+ | 767 | ||||||
+ | 185 | ||||||
TB | RFP | EB | INH | SM | PZA | ||
+ | + | 602 | |||||
+ | + | + | + | 527 | |||
+ | + | + | 518 | ||||
+ | + | 338 | |||||
+ | + | 59 | |||||
+ | + | + | 41 | ||||
+ | + | + | 41 | ||||
+ | + | + | + | 31 | |||
+ | + | + | + | + | 29 | ||
+ | + | + | 27 | ||||
+ | + | + | 24 | ||||
+ | + | + | + | 16 | |||
+ | + | + | 14 | ||||
+ | + | 14 | |||||
+ | + | + | 13 | ||||
+ | + | 12 | |||||
+ | + | 10 | |||||
NTM | RFP | EB | INH | SM | PZA | CAM | |
+ | + | + | 656 | ||||
+ | + | 245 | |||||
+ | + | 133 | |||||
+ | + | 39 | |||||
+ | + | + | 34 | ||||
+ | + | 31 | |||||
+ | + | + | + | 26 | |||
+ | + | + | + | 23 | |||
+ | + | + | 13 | ||||
HZ | VACV | FCV | ACV | VIDA | |||
+ | 15,160 | ||||||
+ | 8731 | ||||||
+ | 1401 | ||||||
+ | 415 |
OI . | Drug . | Patients . | |||||
---|---|---|---|---|---|---|---|
PCP | ST | PM | |||||
+ | 767 | ||||||
+ | 185 | ||||||
TB | RFP | EB | INH | SM | PZA | ||
+ | + | 602 | |||||
+ | + | + | + | 527 | |||
+ | + | + | 518 | ||||
+ | + | 338 | |||||
+ | + | 59 | |||||
+ | + | + | 41 | ||||
+ | + | + | 41 | ||||
+ | + | + | + | 31 | |||
+ | + | + | + | + | 29 | ||
+ | + | + | 27 | ||||
+ | + | + | 24 | ||||
+ | + | + | + | 16 | |||
+ | + | + | 14 | ||||
+ | + | 14 | |||||
+ | + | + | 13 | ||||
+ | + | 12 | |||||
+ | + | 10 | |||||
NTM | RFP | EB | INH | SM | PZA | CAM | |
+ | + | + | 656 | ||||
+ | + | 245 | |||||
+ | + | 133 | |||||
+ | + | 39 | |||||
+ | + | + | 34 | ||||
+ | + | 31 | |||||
+ | + | + | + | 26 | |||
+ | + | + | + | 23 | |||
+ | + | + | 13 | ||||
HZ | VACV | FCV | ACV | VIDA | |||
+ | 15,160 | ||||||
+ | 8731 | ||||||
+ | 1401 | ||||||
+ | 415 |
The running number of the patients for each drug combination is listed. <10 cases are omitted. For PCP and HZ, patients treated with more than the defined dosage of each drug are selected.
OI . | Drug . | Patients . | |||||
---|---|---|---|---|---|---|---|
PCP | ST | PM | |||||
+ | 767 | ||||||
+ | 185 | ||||||
TB | RFP | EB | INH | SM | PZA | ||
+ | + | 602 | |||||
+ | + | + | + | 527 | |||
+ | + | + | 518 | ||||
+ | + | 338 | |||||
+ | + | 59 | |||||
+ | + | + | 41 | ||||
+ | + | + | 41 | ||||
+ | + | + | + | 31 | |||
+ | + | + | + | + | 29 | ||
+ | + | + | 27 | ||||
+ | + | + | 24 | ||||
+ | + | + | + | 16 | |||
+ | + | + | 14 | ||||
+ | + | 14 | |||||
+ | + | + | 13 | ||||
+ | + | 12 | |||||
+ | + | 10 | |||||
NTM | RFP | EB | INH | SM | PZA | CAM | |
+ | + | + | 656 | ||||
+ | + | 245 | |||||
+ | + | 133 | |||||
+ | + | 39 | |||||
+ | + | + | 34 | ||||
+ | + | 31 | |||||
+ | + | + | + | 26 | |||
+ | + | + | + | 23 | |||
+ | + | + | 13 | ||||
HZ | VACV | FCV | ACV | VIDA | |||
+ | 15,160 | ||||||
+ | 8731 | ||||||
+ | 1401 | ||||||
+ | 415 |
OI . | Drug . | Patients . | |||||
---|---|---|---|---|---|---|---|
PCP | ST | PM | |||||
+ | 767 | ||||||
+ | 185 | ||||||
TB | RFP | EB | INH | SM | PZA | ||
+ | + | 602 | |||||
+ | + | + | + | 527 | |||
+ | + | + | 518 | ||||
+ | + | 338 | |||||
+ | + | 59 | |||||
+ | + | + | 41 | ||||
+ | + | + | 41 | ||||
+ | + | + | + | 31 | |||
+ | + | + | + | + | 29 | ||
+ | + | + | 27 | ||||
+ | + | + | 24 | ||||
+ | + | + | + | 16 | |||
+ | + | + | 14 | ||||
+ | + | 14 | |||||
+ | + | + | 13 | ||||
+ | + | 12 | |||||
+ | + | 10 | |||||
NTM | RFP | EB | INH | SM | PZA | CAM | |
+ | + | + | 656 | ||||
+ | + | 245 | |||||
+ | + | 133 | |||||
+ | + | 39 | |||||
+ | + | + | 34 | ||||
+ | + | 31 | |||||
+ | + | + | + | 26 | |||
+ | + | + | + | 23 | |||
+ | + | + | 13 | ||||
HZ | VACV | FCV | ACV | VIDA | |||
+ | 15,160 | ||||||
+ | 8731 | ||||||
+ | 1401 | ||||||
+ | 415 |
The running number of the patients for each drug combination is listed. <10 cases are omitted. For PCP and HZ, patients treated with more than the defined dosage of each drug are selected.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.